Backed by more than SEK 530 million in cash, Saniona is entering the most operationally intensive phase in its history with three wholly owned ion channel programs heading into the clinic. The May AGM struck a more cautious note, as the board withdrew two key proposals in the face of shareholder opposition and pledged to come back with reworked versions. We turned to CEO Thomas Feldthus for a comment.
Read the full interview at biostock.se:
Three shots on goal: Saniona prepares to enter the clinic
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/